Development of a genetically modified nontoxigenic Pasteurella multocida toxin as a candidate for use in vaccines against progressive atrophic rhinitis in pigs

American Journal of Veterinary Research

Volumn 66, Issue 1, 2005, Pages 113-118

  To, Ho ^a   Someno, Shuichi ^a   Nagai, Shinya ^a  

^a NIPPON INSTITUTE FOR BIOLOGICAL SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; BACTERIAL TOXIN; BACTERIAL VACCINE; BACTERIUM ANTIBODY; CYSTEINE; PASTEURELLA MULTOCIDA VACCINE; SERINE; UNCLASSIFIED DRUG; VETERINARY DRUG;

ACTIVE IMMUNIZATION; AMINO ACID SUBSTITUTION; ANIMAL EXPERIMENT; ANTIBODY BLOOD LEVEL; ARTICLE; ATROPHIC RHINITIS; AUTOPSY; BONE ATROPHY; CONTROLLED STUDY; DNA MODIFICATION; DRUG ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FACIAL BONE; GUINEA PIG; IMMUNE RESPONSE; NONHUMAN; PASTEURELLA MULTOCIDA; PROVOCATION TEST; SCORING SYSTEM; SKIN TEST; SWINE DISEASE;

AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; ANIMALS; BACTERIAL PROTEINS; BACTERIAL TOXINS; BACTERIAL VACCINES; ESCHERICHIA COLI; GUINEA PIGS; MICE; PASTEURELLA MULTOCIDA; RHINITIS, ATROPHIC; SWINE; SWINE DISEASES; VACCINES, SYNTHETIC;

ANIMALIA; BACTERIA (MICROORGANISMS); CAVIA PORCELLUS; PASTEURELLA MULTOCIDA; SUS SCROFA;

EID: 13444278877     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2005.66.113     Document Type: Article

References (23)

1. de Jong MF. Progressive and nonprogressive atrophic rhinitis. In: Straw BE, D'Allaire S, Mengeling W, et al, eds. Diseases of swine 8th ed. Ames, Iowa: Iowa State University Press, 1999;355-384.
2. Rimler RB, Brogden KA. Pasteurella multocida isolated from rabbits and swine: serologic types and toxin production. Am J Vet Res 1986;47:730-737.
3. Nagai S, Someno S, Yagihashi T. Differentiation of toxigenic from nontoxigenic isolates of Pasteurella multocida by PCR. J Clin Microbiol 1994;32:1004-1010.
4. van Diemen PM, de Vries RG, Parmentier HK. Immune responses of piglets to Pasteurella multocida toxin and toxoid. Vet Immunol Immunopathol 1994;41:307-321.
5. Foged NT, Nielsen JP, Jorsal SE. Protection against progressive atrophic rhinitis by vaccination with Pasteurella multocida toxin purified by monoclonal antibodies. Vet Rec 1989;125:7-11.
6. Buy WECM, Smith HE, Kamps AMIE, et al. Sequence of the dermonecrotic toxin of Pasteurella multocida ssp. multocida. Nucleic Acids Res 1990;18:2815-2816.
7. Petersen SK. The complete nucleotide sequence of the Pasteurella multocida toxin gene and evidence for a transcriptional repressor, TxaR. Mol Microbiol 1990;4:821-830.
8. Ward PN, Miles AJ, Sumner IG, et al. Activity of the mitogenic Pasteurella multocida toxin requires an essential C-terminal residue. Infect Immun 1998;66:5636-5642.
9. Wilson BA, Ponferrada VG, Vallance JE, et al. Location of the intracellular activity domain of Pasteurella multocida toxin to the N terminus. Infect Immun 1999;67:80-87.
10. Busch C, Orth J, Djouder N, et al. Biological activity of a C-terminal fragment of Pasteurella multocida toxin. Infect Immun 2001; 69:3628-3634.
11. Pullinger GD, Sowdhamini R, Lax AJ. Localization of functional domains of the mitogenic toxin of Pasteurella multocida. Infect Immun 2001;69:7839-7850.
12. Petersen SK, Foged NT, Bording A, et al. Recombinant derivatives of Pasteurella multocida toxin: candidates for a vaccine against progressive atrophic rhinitis. Infect Immun 1991;59:1387-1393.
13. Nielsen JP, Foged NT, Sorensen V, et al. Vaccination against progressive atrophic rhinitis with a recombinant Pasteurella multocida toxin derivative. Can J Vet Res 1991;55:128-138.
14. Barbieri JT, Collier RJ. Expression of a mutant, full-length form of diphtheria toxin in Escherichia coli. Infect Immun 1987; 55:1647-1651.
15. Pizza M, Covacci A, Bartoloni A, et al. Mutants of pertussis toxin suitable for vaccine development. Science 1989;246:497-500.
16. Brendan C. Mutagenesis of cloned DNA. In: Frederick MA, Brent R, Robert EK, et al, eds. Current protocols in molecular biology. Cambridge, UK: John Wiley & Sons Inc, 1995;8.0.1-8.5.9.
17. Reed LJ, Muench H. A simple method for estimating fifty percent endpoints. Am J Hyg 1939;27:493-497.
18. Someno S, Yagihashi T. Atrophic rhinitis caused by toxigenic Pasteurella multocida. Juui-kai 1997;140:64-82.
19. Bording A, Foged NT. Characterization of the immunogenicity of formaldehyde detoxified Pasteurella multocida toxin. Vet Microbiol 1991;29:267-280.
20. Foged NT. Detection of stable epitopes on formaldehydedetoxified Pasteurella multocida toxin by monoclonal antibodies. Vaccine 1991;9:817-823.
21. Wick MJ, Hamood AN, Iglewski BH. Analysis of the structure-function relationship of Pseudomonas aeruginosa exotoxin A. Mol Microbiol 1990;4:527-535.
22. Kashimoto T, Katahira J, Cornejo WR, et al. Identification of functional domains of Bordetella dermonecrotizing toxin. Infect Immun 1999;67:3727-3732.
23. Lemichez M, Flatau G, Bruzzone M, et al. Molecular localization of the Escherichia coli cytotoxic necrotizing factor CNF1 cell-binding and catalytic domains. Mol Microbiol 1997; 24:1061-1070.